logo-loader

Imugene appoints venture capital executive to board

Published: 21:46 19 May 2019 EDT

three empty board seats
It is it well-positioned to progress its commercial and clinical milestones

Imugene Ltd (ASX:IMU) has appointed Dr Jens Eckstein as a non-executive director to its board effective as of today.

Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.

He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.

READ: Imugene to present new data from HER-Vaxx cancer vaccine phase 1b trial

Imugene’s executive chairman Paul Hopper said: “Imugene continues to attract a world class team.

“We welcome Dr Eckstein to the board and look forward to working together to advance our highly promising cancer immuno therapy pipeline.”

Strong pipeline of cancer vaccines in development

The company has a strong pipeline of cancer vaccines in development.

Imugene doses first patient in PD1-Vaxx combination trial

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong speaks with Proactive soon after announcing the first patient has been dosed in the combination cohort of the IMPRINTER study - a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx in combination with...

on 31/5/23